Immunotherapy in new pre-clinical models of HPV-associated oral cancers

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 3, 2013, Pages 534-543

  Paolini, Francesca ^a   Massa, Silvia ^b   Manni, Isabella ^a   Franconi, Rosella ^b   Venuti, Aldo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b ENEA   (Italy)

Author keywords

DNA vaccines; E7 protein; Head and neck tumors; Human papilloma virus; Imaging; Orthotopic models; Plant derived vaccines; Tumor immunity

Indexed keywords

CANCER VACCINE; LICKM E7GGG VACCINE; LUCIFERASE; PCDNA3 E7GGG CP VACCINE; PROTEIN E7; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BIOLUMINESCENCE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; HISTOPATHOLOGY; IMAGING; MONITORING; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PROTEIN ENGINEERING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WART VIRUS; ANIMAL; C3H MOUSE; COMPLICATION; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MOUTH NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; REPORTER GENE; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENES, REPORTER; HUMANS; IMMUNOTHERAPY; LUCIFERASES; MICE, INBRED C3H; MOUTH NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; TREATMENT OUTCOME;

EID: 84874680477     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23232     Document Type: Conference Paper

References (40)

1. Syrjänen S. Human papillomavirus (HPV) in head and neck cancer. J Clinvirol 2005; 32(Suppl 1):S59-66; PMID:15753013; http://dx.doi.org/10.1016/j. jcv.2004.11.017. (Pubitemid 40332590)
2. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006; 24:2606-11; PMID:16763272; http://dx.doi.org/10.1200/JCO.2006.06.1291. (Pubitemid 46622080)
3. American Cancer Society. Cancer Facts and Figures 2012. Atlanta, GA-USA: American Cancer Society, 2012. http://www.cancer.org/Research/ CancerFactsFigures/ACSPC-031941.
4. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010; 11:781-9; PMID:20451455; http://dx.doi.org/10.1016/S1470-2045(10)70017-6.
5. Näsman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009; 125:362-6; PMID:19330833; http://dx.doi.org/10.1002/ijc.24339.
6. Venuti A, Badaracco G, Rizzo C, Mafera B, Rahimi S, Vigili M. Presence of HPV in head and neck tumours: high prevalence in tonsillar localization. J Exp Clin Cancer Res 2004; 23:561-6; PMID:15743024.
7. Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 2002; 21:1510-7; PMID:11896579; http://dx.doi.org/10.1038/sj.onc.1205214. (Pubitemid 34226138)
8. Flohr JK, Lee JH. Identical but different: mechanism of cancer development and response to treatment for human papillomavirus-related and non-related squamous cell cancer of the head and neck. S D Med 2008; 61:453-45, 455; PMID:19266896.
9. Badaracco G, Rizzo C, Mafera B, Pichi B, Giannarelli D, Rahimi S, et al. Molecular analyses and prognostic relevance of HPV in head and neck tumors. Oncol Rep 2007; 7:931-9.
10. Nygård M, Aagnes B, Bray F, Møller B, Mork J. Population-based evidence of increased survival in human papillomavirus-related head and neck cancer. Eur J Cancer 2012; 48:1341-6; PMID:22516210; http://dx.doi.org/10.1016/j.ejca.2012.03.014.
11. Venuti A. Progress and challenges in thevaccine-based treatment of head and neck cancers. J Exp Clin Cancer Res 2009; 28:69; PMID:19473517; http://dx.doi.org/10.1186/1756-9966-28-69.
12. Badaracco G, Venuti A. Human papillomavirus therapeuticvaccines in head and neck tumors. Expert Rev Anticancer Ther 2007; 7:753-66; PMID:17492938; http://dx.doi.org/10.1586/14737140.7.5.753. (Pubitemid 46812956)
13. Su JH, Wu A, Scotney E, Ma B, Monie A, Hung C-F, et al. Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs 2010; 24:109-29; PMID:20199126; http://dx.doi.org/10.2165/11532810-000000000-00000.
14. Giorgi C, Franconi R, Rybicki EP. Human papillomavirusvaccines in plants. Expert Revvaccines 2010; 9:913-24; PMID:20673013; http://dx.doi.org/10.1586/ erv.10.84.
15. Massa S, Franconi R, Brandi R, Muller A, Mett V, Yusibov V, et al. Anti-cancer activity of plant-produced HPV16 E7vaccine.vaccine 2007; 25:3018-21; PMID:17280752; http://dx.doi.org/10.1016/j.vaccine. 2007.01.018. (Pubitemid 46505044)
16. Venuti A, Massa S, Mett V, Vedova LD, Paolini F, Franconi R, et al. An E7-based therapeuticvaccine protects mice against HPV16 associated cancer.vaccine 2009; 27:3395-7; PMID:19200826; http://dx.doi.org/10.1016/j. vaccine.2009.01.068.
17. Massa S, Simeone P, Muller A, Benvenuto E, Venuti A, Franconi R. Antitumor activity of DNAvaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein. Hum Gene Ther 2008; 19:354-64; PMID:18439124; http://dx.doi.org/10.1089/hum.2007.122. (Pubitemid 351591427)
18. Massa S, Paolini F, Spanò L, Franconi R, Venuti A. Mutants of plant genes for developing cancervaccines. Hum Vaccin 2011; 7(Suppl):147-55; PMID:21266841; http://dx.doi.org/10.4161/hv.7.0.14577.
19. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23:2242-9; PMID:7690326; http://dx.doi.org/10.1002/ eji.1830230929. (Pubitemid 23265889)
20. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novelvaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56:21-6; PMID:8548765.
21. Ji H, Chang EY, Lin KY, Kurman RJ, Pardoll DM, Wu TC. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer 1998; 78:41-5; PMID:9724092; http://dx.doi.org/10.1002/(SICI)1097-0215(19980925)78:1< 41::AIDIJC8> 3.0.CO;2-X.
22. Decrausaz L, Gonçalves AR, Domingos-Pereira S, Pythoud C, Stehle JC, Schiller J, et al. A novel mucosal orthotopic murine model of human papillomavirus-associated genital cancers. Int J Cancer 2011; 128:2105-13; PMID:20635385; http://dx.doi.org/10.1002/ijc.25561.
23. Lou E, Kellman RM, Hutchison R, Shillitoe EJ. Clinical and pathological features of the murine AT-84 orthotopic model of oral cancer. Oral Dis 2003; 9:305-12; PMID:14629332; http://dx.doi.org/10.1034/j.1601-0825.2003.00968.x. (Pubitemid 37420495)
24. Schultz-Hector S, Haghayegh S. Beta-fibroblast growth factor expression in human and murine squamous cell carcinomas and its relationship to regional endothelial cell proliferation. Cancer Res 1993; 53:1444-9; PMID:7680286. (Pubitemid 23097130)
25. Dinesman A, Haughey B, Gates GA, Aufdemorte T, Von Hoff DD. Development of a new in vivo model for head and neck cancer. Otolaryngol Head Neck Surg 1990; 103:766-74; PMID:2126099.
26. Lorenzon L, Mazzetta F, Venuti A, Frega A, Torrisi MR, French D. In vivo HPV 16 E5 mRNA: expression pattern in patients with squamous intra-epithelial lesions of the cervix. J Clinvirol 2011; 52:79-83; PMID:21767984; http://dx.doi.org/10.1016/j.jcv.2011.06.007.
27. Syrjänen K, Syrjänen S, Lamberg M, Pyrhönen S, Nuutinen J. Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J Oral Surg 1983; 12:418-24; PMID:6325356; http://dx.doi.org/10.1016/S0300-9785(83)80033-7. (Pubitemid 14141093)
28. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363:24-35; PMID:20530316; http://dx.doi.org/10.1056/ NEJMoa0912217.
29. Mognetti B, Di Carlo F, Berta GN. Animal models in oral cancer research. Oral Oncol 2006; 42:448-60; PMID:16266822; http://dx.doi.org/10.1016/j. oraloncology.2005.07.014.
30. Hotz HG, Hines OJ, Foitzik T, Reber HA. Animal models of exocrine pancreatic cancer. Int J Colorectal Dis 2000; 15:136-43; PMID:10954185; http://dx.doi.org/10.1007/s003840000229.
31. Stakleff KD, Von Gruenigen VE. Rodent models for ovarian cancer research. Int J Gynecol Cancer 2003; 13:405-12; PMID:12911715; http://dx.doi.org/10.1046/ j.1525-1438.2003.13317.x. (Pubitemid 38220657)
32. Marx J. Medicine. Building better mouse models for studying cancer. Science 2003; 299:1972-5; PMID:12663895; http://dx.doi.org/10.1126/science. 299.5615.1972.
33. Kwak I, Tsai SY, DeMayo FJ. Genetically engineered mouse models for lung cancer. Annu Rev Physiol 2004; 66:647-63; PMID:14977417; http://dx.doi.org/10. 1146/annurev.physiol.66.032102.134301. (Pubitemid 40614458)
34. Cui N, Nomura T, Noma H, Yokoo K, Takagi R, Hashimoto S, et al. Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice. Clin Cancer Res 2005; 11:2713-9; PMID:15814653; http://dx.doi.org/10.1158/ 1078-0432.CCR-04-1767. (Pubitemid 40569473)
35. Schantz SP, Shillitoe EJ, Brown B, Campbell B. Natural killer cell activity and head and neck cancer: a clinical assessment. J Natl Cancer Inst 1986; 77:869-75; PMID:3020297. (Pubitemid 16031849)
36. Woodland DL. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004; 25:98-104; PMID:15102369; http://dx.doi.org/10.1016/j. it.2003.11.009.
37. Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, et al. A phase I trial of a human papillomavirus DNAvaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 2009; 15:361-7; PMID:19118066; http://dx.doi.org/10.1158/1078-0432.CCR-08-1725.
38. Hier MP, Black MJ, Shenouda G, Sadeghi N, Karp SE. A murine model for the immunotherapy of head and neck squamous cell carcinoma. Laryngoscope 1995; 105:1077-80; PMID:7564839; http://dx.doi.org/10.1288/00005537-199510000-00013.
39. Brasier AR, Tate JE, Habener JF. Optimized use of the firefly luciferase assay as a reporter gene in mammalian cell lines. Biotechniques 1989; 7:1116-22; PMID:2698191.
40. Cattani P, Siddu A, D'Onghia S, Marchetti S, Santangelo R, Vellone VG, et al. RNA (E6 and E7) assays versus DNA (E6 and E7) assays for risk evaluation for women infected with human papillomavirus. J Clin Microbiol 2009; 47:2136-41; PMID:19403762; http://dx.doi.org/10.1128/JCM.01733-08.